董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nailesh Bhatt | 男 | Director | 53 | 5.83万美元 | 未持股 | 2025-09-26 |
| Albert Dyrness | 男 | Director | 62 | 5.98万美元 | 未持股 | 2025-09-26 |
| Donald Griffith | 男 | Chief Financial Officer and Director | 77 | 9.39万美元 | 未持股 | 2025-09-26 |
| Raghu Rao | 男 | Interim Chief Executive Officer and Director | 63 | 12.08万美元 | 未持股 | 2025-09-26 |
| Lori McNeill | 女 | Director | 53 | 6.43万美元 | 未持股 | 2025-09-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald Griffith | 男 | Chief Financial Officer and Director | 77 | 9.39万美元 | 未持股 | 2025-09-26 |
| Raghu Rao | 男 | Interim Chief Executive Officer and Director | 63 | 12.08万美元 | 未持股 | 2025-09-26 |
| John K. Cini | 男 | Chief Scientific Officer | 73 | 41.97万美元 | 未持股 | 2025-09-26 |
| Susan Dexter | 女 | Chief Technical Officer | 70 | 未披露 | 未持股 | 2025-09-26 |
| Richard Kenny | 男 | Chief Medical Officer | 66 | 未披露 | 未持股 | 2025-09-26 |
| Stephen McAndrew | 男 | President and Chief Business Officer | 71 | 未披露 | 未持股 | 2025-09-26 |
董事简历
中英对照 | 中文 | 英文- Nailesh Bhatt
-
Nailesh Bhatt自2018年7月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。自2018年1月以来，Bhatt先生一直担任Vgyaan Pharmaceuticals LLC（一家专注于开发和商业化临床关键药物的公司）的首席执行官兼董事会成员。在此之前，Bhatt先生于2001年11月创立了Proximare，并担任其董事总经理。Proximare是一家战略咨询公司，专注于制药行业。自2018年4月起，他还担任Azurity Pharmaceuticals，Inc.的董事会成员。2015年6月，Bhatt先生创立了Proximare LifeSciences Fund。Bhatt先生在波士顿大学（Boston University）攻读文学学士学位，主修生物学。
Nailesh Bhatt serves as a member of Pubco Board following the Closing. Mr. Bhatt has been the Chief Executive Officer of VGYAAN Pharmaceuticals LLC ("VGYAAN"), a company foced on developing and commercializing clinically critical drugs. Mr. Bhatt was also a Board Member of VGYAAN until June 2023. Prior to that, in November 2001, Mr. Bhatt founded Proximare and is its Managing Director. Proximare is a strategic advisory firm foced exclively on the pharmaceutical indtry. Mr. Bhatt also serves as a Board Member of Azurity Pharmaceuticals, Inc., CoreRx Pharma and Spectra Medical Devices. In June 2015, Mr. Bhatt founded Proximare Lifesciences Fund. Mr. Bhatt pursued a Bachelor of Arts at Boston University with a major in Biology. - Nailesh Bhatt自2018年7月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。自2018年1月以来，Bhatt先生一直担任Vgyaan Pharmaceuticals LLC（一家专注于开发和商业化临床关键药物的公司）的首席执行官兼董事会成员。在此之前，Bhatt先生于2001年11月创立了Proximare，并担任其董事总经理。Proximare是一家战略咨询公司，专注于制药行业。自2018年4月起，他还担任Azurity Pharmaceuticals，Inc.的董事会成员。2015年6月，Bhatt先生创立了Proximare LifeSciences Fund。Bhatt先生在波士顿大学（Boston University）攻读文学学士学位，主修生物学。
- Nailesh Bhatt serves as a member of Pubco Board following the Closing. Mr. Bhatt has been the Chief Executive Officer of VGYAAN Pharmaceuticals LLC ("VGYAAN"), a company foced on developing and commercializing clinically critical drugs. Mr. Bhatt was also a Board Member of VGYAAN until June 2023. Prior to that, in November 2001, Mr. Bhatt founded Proximare and is its Managing Director. Proximare is a strategic advisory firm foced exclively on the pharmaceutical indtry. Mr. Bhatt also serves as a Board Member of Azurity Pharmaceuticals, Inc., CoreRx Pharma and Spectra Medical Devices. In June 2015, Mr. Bhatt founded Proximare Lifesciences Fund. Mr. Bhatt pursued a Bachelor of Arts at Boston University with a major in Biology.
- Albert Dyrness
-
Albert Dyrness自2019年10月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Dyrness先生是公认的生物制药行业专家生物工艺工程，在上游，下游和填充/完成过程中拥有专业知识。Dyrness先生自2019年7月起担任Trinity Consultants Company Advent Engineering Services，Inc.的董事总经理，该公司是其生命科学部门。1988年，Dyrness先生联合创立了Advent Engineering Services，Inc.，这是一家服务于能源和生命科学行业的工程咨询公司。Advent在旧金山湾区仅有4名员工，现已发展为130多名工程师，在加拿大多伦多、新加坡、北卡罗来纳州罗利、俄勒冈州波特兰、马萨诸塞州波士顿、尔湾和加利福尼亚州圣拉蒙设有办事处。Dyrness先生于2016年成为Advent的总裁兼首席技术官，并于2017年指导公司与Trinity Consultants合并，Trinity Consultants是一家700人的工程咨询公司。他也曾担任Oncobiologics，Inc.的董事会成员。听我说OutlookTherapeutics，Inc.纳斯达克:OTLK于2015年12月至2017年9月。1986年Dyrness先生毕业于麻省理工学院（Massachusetts Institute of Technology），在那里他学习机械工程和企业家精神。
Albert Dyrness serves as a member of Pubco Board following the Closing. Mr. Dyrness is a recognized biopharmaceutical indtry expert in bio process engineering with expertise in upstream, downstream, and fill/finish processes. Since July 2019, Mr. Dyrness has been the Managing Director of ADVENT Engineering Services, Inc., a Trinity Consultants Company, which serves as its life sciences division. In 1988, Mr. Dyrness Co Founded ADVENT Engineering Services, Inc., an engineering consulting firm serving the energy and life sciences indtries. Starting with only 4 employees in the San Francisco Bay Area, ADVENT has grown to a staff of over 130 engineers with offices in Toronto, Canada, Singapore, Raleigh, North Carolina, Portland Oregon, Boston, Massachetts, Irvine and San Ramon, California. In 2016, Mr. Dyrness became President and Chief Technical Officer of ADVENT and, in 2017, guided the company to a merger with Trinity Consultants, a 700 person engineering consulting firm. He also served as a member of the board of directors of Oncobiologics, Inc. (now Outlook Therapeutics, Inc.; Nasdaq: OTLK) from December 2015 to September 2017. In 1986, Mr. Dyrness graduated from the Massachetts Institute of Technology where he studied mechanical engineering and entrepreneurism. - Albert Dyrness自2019年10月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Dyrness先生是公认的生物制药行业专家生物工艺工程，在上游，下游和填充/完成过程中拥有专业知识。Dyrness先生自2019年7月起担任Trinity Consultants Company Advent Engineering Services，Inc.的董事总经理，该公司是其生命科学部门。1988年，Dyrness先生联合创立了Advent Engineering Services，Inc.，这是一家服务于能源和生命科学行业的工程咨询公司。Advent在旧金山湾区仅有4名员工，现已发展为130多名工程师，在加拿大多伦多、新加坡、北卡罗来纳州罗利、俄勒冈州波特兰、马萨诸塞州波士顿、尔湾和加利福尼亚州圣拉蒙设有办事处。Dyrness先生于2016年成为Advent的总裁兼首席技术官，并于2017年指导公司与Trinity Consultants合并，Trinity Consultants是一家700人的工程咨询公司。他也曾担任Oncobiologics，Inc.的董事会成员。听我说OutlookTherapeutics，Inc.纳斯达克:OTLK于2015年12月至2017年9月。1986年Dyrness先生毕业于麻省理工学院（Massachusetts Institute of Technology），在那里他学习机械工程和企业家精神。
- Albert Dyrness serves as a member of Pubco Board following the Closing. Mr. Dyrness is a recognized biopharmaceutical indtry expert in bio process engineering with expertise in upstream, downstream, and fill/finish processes. Since July 2019, Mr. Dyrness has been the Managing Director of ADVENT Engineering Services, Inc., a Trinity Consultants Company, which serves as its life sciences division. In 1988, Mr. Dyrness Co Founded ADVENT Engineering Services, Inc., an engineering consulting firm serving the energy and life sciences indtries. Starting with only 4 employees in the San Francisco Bay Area, ADVENT has grown to a staff of over 130 engineers with offices in Toronto, Canada, Singapore, Raleigh, North Carolina, Portland Oregon, Boston, Massachetts, Irvine and San Ramon, California. In 2016, Mr. Dyrness became President and Chief Technical Officer of ADVENT and, in 2017, guided the company to a merger with Trinity Consultants, a 700 person engineering consulting firm. He also served as a member of the board of directors of Oncobiologics, Inc. (now Outlook Therapeutics, Inc.; Nasdaq: OTLK) from December 2015 to September 2017. In 1986, Mr. Dyrness graduated from the Massachetts Institute of Technology where he studied mechanical engineering and entrepreneurism.
- Donald Griffith
-
Donald Griffith自2015年4月十四行诗成立以来一直在十四行诗董事会任职，并于2015年4月至2018年6月担任十四行诗董事会主席，并于合并结束时被任命为董事会成员。Griffith先生自2019年1月1日起担任十四行诗财务总监，自合并起担任我们的财务总监。在担任财务总监之前，他曾于2015年4月至2016年12月担任十四行诗首席执行官兼首席财务官。在此之前，Griffith先生是Oncobiologics Inc.的首席财务官、董事和秘书。现在Outlook Therapeutics NASDAQ:OTLK从2011年到2018年。Griffith先生拥有超过40年的财务和会计经验，是新泽西州会计师事务所Stolz&Griffith，LLC的创始人兼合伙人。
Donald Griffith,has served as Sonnet's Financial Controller since January 1, 2019, and since the Merger serves as Sonnet Biotherapeutics Holdings, Inc. Controller. Prior to being Financial Controller, he served as Sonnet's Chief Executive Officer and Chief Financial Officer from April 2015 to December 2016. Before that, Mr. Griffith was the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (now Outlook Therapeutics; Nasdaq: OTLK) from 2011 to 2018. Mr. Griffith has over 40 years' experience in finance and accounting and is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm. - Donald Griffith自2015年4月十四行诗成立以来一直在十四行诗董事会任职，并于2015年4月至2018年6月担任十四行诗董事会主席，并于合并结束时被任命为董事会成员。Griffith先生自2019年1月1日起担任十四行诗财务总监，自合并起担任我们的财务总监。在担任财务总监之前，他曾于2015年4月至2016年12月担任十四行诗首席执行官兼首席财务官。在此之前，Griffith先生是Oncobiologics Inc.的首席财务官、董事和秘书。现在Outlook Therapeutics NASDAQ:OTLK从2011年到2018年。Griffith先生拥有超过40年的财务和会计经验，是新泽西州会计师事务所Stolz&Griffith，LLC的创始人兼合伙人。
- Donald Griffith,has served as Sonnet's Financial Controller since January 1, 2019, and since the Merger serves as Sonnet Biotherapeutics Holdings, Inc. Controller. Prior to being Financial Controller, he served as Sonnet's Chief Executive Officer and Chief Financial Officer from April 2015 to December 2016. Before that, Mr. Griffith was the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (now Outlook Therapeutics; Nasdaq: OTLK) from 2011 to 2018. Mr. Griffith has over 40 years' experience in finance and accounting and is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm.
- Raghu Rao
-
Raghu Rao自2019年11月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Rao先生是一位连续创业者、战略业务顾问和天使投资人。Rao先生曾与多家高科技公司创立，扩大规模并成功退出。在他33年的职业生涯中，Rao先生为客户提供了有关高调项目的战略和推出的建议，例如USA.gov，TSA Screening Gateway，Cancer.gov和其他电子政务计划。作为Vistage Princeton的主席，从2012年7月至2017年3月，Rao先生为总收入超过20亿美元的公司的中间市场首席执行官和商业领袖运营了三个高绩效的同行咨询委员会。Rao从1995年8月到2008年7月担任Infozen董事长和总裁，管理超过10亿美元的美国联邦政府合同。Rao先生是Indus Entrepreneurs Tie.org的20年特许会员和the Indiaspora的5年赞助人。他曾担任多家公司的董事会职务，包括Cellix Biosciences（2016年1月至2017年1月）、Paper Battery Company（2009年1月至2018年12月）、Kovid Group（2016年2月至2017年10月）、Wiznucleus（2010年6月至今）和Infozen（1995年8月至2008年7月）。Rao先生活跃在社会创业和社区服务领域。他于2012年12月共同创立了印度教犹太联盟，并于2007年3月共同创立了宗教自由论坛，以维护世界各地的宗教多样性。他曾担任the Infinity Foundation（新泽西）、Arsha Vidya Gurukulam（宾夕法尼亚州）和the Family Services Agency（马里兰州）的非营利董事会职务。Rao先生拥有George Washington University金融学工商管理硕士学位（1991年12月），Virginia Tech计算机科学硕士学位（1986年12月）和B.Tech。Indian Institute of Technology，Madras的电气工程学位（1984年6月）。
Raghu Rao,is a serial entrepreneur, strategic business advisor and angel investor. Mr. Rao has founded, scaled and had successful exits with several high-technology companies. In his 33-year career, Mr. Rao has advised clients on the strategy and roll-out of high-profile projects, such as USA.gov, TSA Screening Gateway, Cancer.gov and other eGovernment initiatives. As the Vistage Princeton Chair, from July 2012 to March 2017, Mr. Rao ran three high-performing peer advisory boards for middle-market CEOs and business leaders of companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen from August 1995 to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. Mr. Rao is a 20-year Charter Member of The Indus Entrepreneurs (TiE.org) and a 5-year patron of the Indiaspora. He has held board positions at several companies including Cellix BioSciences (Jan 2016 - Jan 2017), Paper Battery Company (Jan 2009 - Dec 2018), Kovid Group (Feb 2016 - Oct 2017) , WizNucleus (Jun 2010 - present) and InfoZen (Aug 1995 - Jul 2008). Mr. Rao is active in social entrepreneurship and community service. He co-founded the Hindu Jewish Coalition in December 2012 and Forum for Religious Freedom in March 2007, to preserve religious diversity worldwide. He has held non-profit board positions at the Infinity Foundation (New Jersey), Arsha Vidya Gurukulam (Pennsylvania) and the Family Services Agency (Maryland). Mr. Rao has an MBA in Finance from George Washington University (Dec 1991), an M.S. in Computer Science from Virginia Tech (Dec 1986), and a B.Tech. in Electrical Engineering from Indian Institute of Technology Madras (June 1984). - Raghu Rao自2019年11月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Rao先生是一位连续创业者、战略业务顾问和天使投资人。Rao先生曾与多家高科技公司创立，扩大规模并成功退出。在他33年的职业生涯中，Rao先生为客户提供了有关高调项目的战略和推出的建议，例如USA.gov，TSA Screening Gateway，Cancer.gov和其他电子政务计划。作为Vistage Princeton的主席，从2012年7月至2017年3月，Rao先生为总收入超过20亿美元的公司的中间市场首席执行官和商业领袖运营了三个高绩效的同行咨询委员会。Rao从1995年8月到2008年7月担任Infozen董事长和总裁，管理超过10亿美元的美国联邦政府合同。Rao先生是Indus Entrepreneurs Tie.org的20年特许会员和the Indiaspora的5年赞助人。他曾担任多家公司的董事会职务，包括Cellix Biosciences（2016年1月至2017年1月）、Paper Battery Company（2009年1月至2018年12月）、Kovid Group（2016年2月至2017年10月）、Wiznucleus（2010年6月至今）和Infozen（1995年8月至2008年7月）。Rao先生活跃在社会创业和社区服务领域。他于2012年12月共同创立了印度教犹太联盟，并于2007年3月共同创立了宗教自由论坛，以维护世界各地的宗教多样性。他曾担任the Infinity Foundation（新泽西）、Arsha Vidya Gurukulam（宾夕法尼亚州）和the Family Services Agency（马里兰州）的非营利董事会职务。Rao先生拥有George Washington University金融学工商管理硕士学位（1991年12月），Virginia Tech计算机科学硕士学位（1986年12月）和B.Tech。Indian Institute of Technology，Madras的电气工程学位（1984年6月）。
- Raghu Rao,is a serial entrepreneur, strategic business advisor and angel investor. Mr. Rao has founded, scaled and had successful exits with several high-technology companies. In his 33-year career, Mr. Rao has advised clients on the strategy and roll-out of high-profile projects, such as USA.gov, TSA Screening Gateway, Cancer.gov and other eGovernment initiatives. As the Vistage Princeton Chair, from July 2012 to March 2017, Mr. Rao ran three high-performing peer advisory boards for middle-market CEOs and business leaders of companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen from August 1995 to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. Mr. Rao is a 20-year Charter Member of The Indus Entrepreneurs (TiE.org) and a 5-year patron of the Indiaspora. He has held board positions at several companies including Cellix BioSciences (Jan 2016 - Jan 2017), Paper Battery Company (Jan 2009 - Dec 2018), Kovid Group (Feb 2016 - Oct 2017) , WizNucleus (Jun 2010 - present) and InfoZen (Aug 1995 - Jul 2008). Mr. Rao is active in social entrepreneurship and community service. He co-founded the Hindu Jewish Coalition in December 2012 and Forum for Religious Freedom in March 2007, to preserve religious diversity worldwide. He has held non-profit board positions at the Infinity Foundation (New Jersey), Arsha Vidya Gurukulam (Pennsylvania) and the Family Services Agency (Maryland). Mr. Rao has an MBA in Finance from George Washington University (Dec 1991), an M.S. in Computer Science from Virginia Tech (Dec 1986), and a B.Tech. in Electrical Engineering from Indian Institute of Technology Madras (June 1984).
- Lori McNeill
-
Lori McNeill，自2016年起担任McNeill Consulting， LLC的创始人兼首席执行官，该公司是一家管理咨询公司，专注于培养更有效的领导者，并确保变革管理计划无缝进行。McNeill女士在医疗保健行业拥有超过20年的经验，其中13年任职于Pfizer Inc.，其中包括担任综合医疗业务部门Chief of Staff of Global Operations。从2020年到2021年，她担任Global PPE， Inc.的首席运营官兼董事会主席，Global PPE, Inc.是一家全球个人防护设备和安全用品供应商，专注于医疗保健和政府实体，以对抗COVID-19大流行。她曾获得多个机构的认可：全球国际贸易促进委员会（Global Council for Promotion of International Trade， 2021）全球100位最具领导力女性；2021年Changemakers Summit奖得主；女性领导力现状——HR.com 2020年封面文章；2011年获得辉瑞国际创新卓越奖，目前是Womenomics的全球主席。
Lori McNeill,is the founder and Chief Executive Officer of McNeill Consulting, LLC since 2016, a management consulting company focused on developing leaders to be more effective and ensuring that change management initiatives are seamless. Ms. McNeill has over twenty years' experience in the healthcare industry, thirteen of which were at Pfizer Inc., which included working as the Chief of Staff of Global Operations in the Integrated Health Business unit. From 2020 to 2021, Ms. McNeill was the Chief Operating Officer and Chairperson of the board of directors of Global PPE, Inc., a worldwide supplier of personal protective equipment and safety supplies focused on healthcare and government entities to fight the COVID-19 pandemic. She has been recognized by several institutions: Top 100 Global Women in Leadership - Global Council for the Promotion of International Trade, 2021; Changemakers Summit Award Winner, 2021; The State of Women in Leadership - Cover article for HR.com, 2020; and Pfizer International Innovation Excellence Award, 2011 and is currently Global Chairperson of Womenomics. - Lori McNeill，自2016年起担任McNeill Consulting， LLC的创始人兼首席执行官，该公司是一家管理咨询公司，专注于培养更有效的领导者，并确保变革管理计划无缝进行。McNeill女士在医疗保健行业拥有超过20年的经验，其中13年任职于Pfizer Inc.，其中包括担任综合医疗业务部门Chief of Staff of Global Operations。从2020年到2021年，她担任Global PPE， Inc.的首席运营官兼董事会主席，Global PPE, Inc.是一家全球个人防护设备和安全用品供应商，专注于医疗保健和政府实体，以对抗COVID-19大流行。她曾获得多个机构的认可：全球国际贸易促进委员会（Global Council for Promotion of International Trade， 2021）全球100位最具领导力女性；2021年Changemakers Summit奖得主；女性领导力现状——HR.com 2020年封面文章；2011年获得辉瑞国际创新卓越奖，目前是Womenomics的全球主席。
- Lori McNeill,is the founder and Chief Executive Officer of McNeill Consulting, LLC since 2016, a management consulting company focused on developing leaders to be more effective and ensuring that change management initiatives are seamless. Ms. McNeill has over twenty years' experience in the healthcare industry, thirteen of which were at Pfizer Inc., which included working as the Chief of Staff of Global Operations in the Integrated Health Business unit. From 2020 to 2021, Ms. McNeill was the Chief Operating Officer and Chairperson of the board of directors of Global PPE, Inc., a worldwide supplier of personal protective equipment and safety supplies focused on healthcare and government entities to fight the COVID-19 pandemic. She has been recognized by several institutions: Top 100 Global Women in Leadership - Global Council for the Promotion of International Trade, 2021; Changemakers Summit Award Winner, 2021; The State of Women in Leadership - Cover article for HR.com, 2020; and Pfizer International Innovation Excellence Award, 2011 and is currently Global Chairperson of Womenomics.
高管简历
中英对照 | 中文 | 英文- Donald Griffith
Donald Griffith自2015年4月十四行诗成立以来一直在十四行诗董事会任职，并于2015年4月至2018年6月担任十四行诗董事会主席，并于合并结束时被任命为董事会成员。Griffith先生自2019年1月1日起担任十四行诗财务总监，自合并起担任我们的财务总监。在担任财务总监之前，他曾于2015年4月至2016年12月担任十四行诗首席执行官兼首席财务官。在此之前，Griffith先生是Oncobiologics Inc.的首席财务官、董事和秘书。现在Outlook Therapeutics NASDAQ:OTLK从2011年到2018年。Griffith先生拥有超过40年的财务和会计经验，是新泽西州会计师事务所Stolz&Griffith，LLC的创始人兼合伙人。
Donald Griffith,has served as Sonnet's Financial Controller since January 1, 2019, and since the Merger serves as Sonnet Biotherapeutics Holdings, Inc. Controller. Prior to being Financial Controller, he served as Sonnet's Chief Executive Officer and Chief Financial Officer from April 2015 to December 2016. Before that, Mr. Griffith was the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (now Outlook Therapeutics; Nasdaq: OTLK) from 2011 to 2018. Mr. Griffith has over 40 years' experience in finance and accounting and is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm.- Donald Griffith自2015年4月十四行诗成立以来一直在十四行诗董事会任职，并于2015年4月至2018年6月担任十四行诗董事会主席，并于合并结束时被任命为董事会成员。Griffith先生自2019年1月1日起担任十四行诗财务总监，自合并起担任我们的财务总监。在担任财务总监之前，他曾于2015年4月至2016年12月担任十四行诗首席执行官兼首席财务官。在此之前，Griffith先生是Oncobiologics Inc.的首席财务官、董事和秘书。现在Outlook Therapeutics NASDAQ:OTLK从2011年到2018年。Griffith先生拥有超过40年的财务和会计经验，是新泽西州会计师事务所Stolz&Griffith，LLC的创始人兼合伙人。
- Donald Griffith,has served as Sonnet's Financial Controller since January 1, 2019, and since the Merger serves as Sonnet Biotherapeutics Holdings, Inc. Controller. Prior to being Financial Controller, he served as Sonnet's Chief Executive Officer and Chief Financial Officer from April 2015 to December 2016. Before that, Mr. Griffith was the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (now Outlook Therapeutics; Nasdaq: OTLK) from 2011 to 2018. Mr. Griffith has over 40 years' experience in finance and accounting and is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm.
- Raghu Rao
Raghu Rao自2019年11月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Rao先生是一位连续创业者、战略业务顾问和天使投资人。Rao先生曾与多家高科技公司创立，扩大规模并成功退出。在他33年的职业生涯中，Rao先生为客户提供了有关高调项目的战略和推出的建议，例如USA.gov，TSA Screening Gateway，Cancer.gov和其他电子政务计划。作为Vistage Princeton的主席，从2012年7月至2017年3月，Rao先生为总收入超过20亿美元的公司的中间市场首席执行官和商业领袖运营了三个高绩效的同行咨询委员会。Rao从1995年8月到2008年7月担任Infozen董事长和总裁，管理超过10亿美元的美国联邦政府合同。Rao先生是Indus Entrepreneurs Tie.org的20年特许会员和the Indiaspora的5年赞助人。他曾担任多家公司的董事会职务，包括Cellix Biosciences（2016年1月至2017年1月）、Paper Battery Company（2009年1月至2018年12月）、Kovid Group（2016年2月至2017年10月）、Wiznucleus（2010年6月至今）和Infozen（1995年8月至2008年7月）。Rao先生活跃在社会创业和社区服务领域。他于2012年12月共同创立了印度教犹太联盟，并于2007年3月共同创立了宗教自由论坛，以维护世界各地的宗教多样性。他曾担任the Infinity Foundation（新泽西）、Arsha Vidya Gurukulam（宾夕法尼亚州）和the Family Services Agency（马里兰州）的非营利董事会职务。Rao先生拥有George Washington University金融学工商管理硕士学位（1991年12月），Virginia Tech计算机科学硕士学位（1986年12月）和B.Tech。Indian Institute of Technology，Madras的电气工程学位（1984年6月）。
Raghu Rao,is a serial entrepreneur, strategic business advisor and angel investor. Mr. Rao has founded, scaled and had successful exits with several high-technology companies. In his 33-year career, Mr. Rao has advised clients on the strategy and roll-out of high-profile projects, such as USA.gov, TSA Screening Gateway, Cancer.gov and other eGovernment initiatives. As the Vistage Princeton Chair, from July 2012 to March 2017, Mr. Rao ran three high-performing peer advisory boards for middle-market CEOs and business leaders of companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen from August 1995 to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. Mr. Rao is a 20-year Charter Member of The Indus Entrepreneurs (TiE.org) and a 5-year patron of the Indiaspora. He has held board positions at several companies including Cellix BioSciences (Jan 2016 - Jan 2017), Paper Battery Company (Jan 2009 - Dec 2018), Kovid Group (Feb 2016 - Oct 2017) , WizNucleus (Jun 2010 - present) and InfoZen (Aug 1995 - Jul 2008). Mr. Rao is active in social entrepreneurship and community service. He co-founded the Hindu Jewish Coalition in December 2012 and Forum for Religious Freedom in March 2007, to preserve religious diversity worldwide. He has held non-profit board positions at the Infinity Foundation (New Jersey), Arsha Vidya Gurukulam (Pennsylvania) and the Family Services Agency (Maryland). Mr. Rao has an MBA in Finance from George Washington University (Dec 1991), an M.S. in Computer Science from Virginia Tech (Dec 1986), and a B.Tech. in Electrical Engineering from Indian Institute of Technology Madras (June 1984).- Raghu Rao自2019年11月起担任十四行诗董事会成员，并在合并结束时被任命为董事会成员。Rao先生是一位连续创业者、战略业务顾问和天使投资人。Rao先生曾与多家高科技公司创立，扩大规模并成功退出。在他33年的职业生涯中，Rao先生为客户提供了有关高调项目的战略和推出的建议，例如USA.gov，TSA Screening Gateway，Cancer.gov和其他电子政务计划。作为Vistage Princeton的主席，从2012年7月至2017年3月，Rao先生为总收入超过20亿美元的公司的中间市场首席执行官和商业领袖运营了三个高绩效的同行咨询委员会。Rao从1995年8月到2008年7月担任Infozen董事长和总裁，管理超过10亿美元的美国联邦政府合同。Rao先生是Indus Entrepreneurs Tie.org的20年特许会员和the Indiaspora的5年赞助人。他曾担任多家公司的董事会职务，包括Cellix Biosciences（2016年1月至2017年1月）、Paper Battery Company（2009年1月至2018年12月）、Kovid Group（2016年2月至2017年10月）、Wiznucleus（2010年6月至今）和Infozen（1995年8月至2008年7月）。Rao先生活跃在社会创业和社区服务领域。他于2012年12月共同创立了印度教犹太联盟，并于2007年3月共同创立了宗教自由论坛，以维护世界各地的宗教多样性。他曾担任the Infinity Foundation（新泽西）、Arsha Vidya Gurukulam（宾夕法尼亚州）和the Family Services Agency（马里兰州）的非营利董事会职务。Rao先生拥有George Washington University金融学工商管理硕士学位（1991年12月），Virginia Tech计算机科学硕士学位（1986年12月）和B.Tech。Indian Institute of Technology，Madras的电气工程学位（1984年6月）。
- Raghu Rao,is a serial entrepreneur, strategic business advisor and angel investor. Mr. Rao has founded, scaled and had successful exits with several high-technology companies. In his 33-year career, Mr. Rao has advised clients on the strategy and roll-out of high-profile projects, such as USA.gov, TSA Screening Gateway, Cancer.gov and other eGovernment initiatives. As the Vistage Princeton Chair, from July 2012 to March 2017, Mr. Rao ran three high-performing peer advisory boards for middle-market CEOs and business leaders of companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen from August 1995 to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. Mr. Rao is a 20-year Charter Member of The Indus Entrepreneurs (TiE.org) and a 5-year patron of the Indiaspora. He has held board positions at several companies including Cellix BioSciences (Jan 2016 - Jan 2017), Paper Battery Company (Jan 2009 - Dec 2018), Kovid Group (Feb 2016 - Oct 2017) , WizNucleus (Jun 2010 - present) and InfoZen (Aug 1995 - Jul 2008). Mr. Rao is active in social entrepreneurship and community service. He co-founded the Hindu Jewish Coalition in December 2012 and Forum for Religious Freedom in March 2007, to preserve religious diversity worldwide. He has held non-profit board positions at the Infinity Foundation (New Jersey), Arsha Vidya Gurukulam (Pennsylvania) and the Family Services Agency (Maryland). Mr. Rao has an MBA in Finance from George Washington University (Dec 1991), an M.S. in Computer Science from Virginia Tech (Dec 1986), and a B.Tech. in Electrical Engineering from Indian Institute of Technology Madras (June 1984).
- John K. Cini
John K.Cini，他于2015年共同创立十四行诗，并一直担任其首席科学官，并于合并结束时被任命为公司的首席科学官，在那里他负责监督和指导公司的发现和开发计划。他的角色包括监督癌症和免疫肿瘤学目标的选择过程和概念验证测试。在加入十四行诗之前，他曾于2011年1月至2015年4月担任OncoBiologics，Inc.的发现和开发科学Vice President。他从Discovery公司到IND公司成功推进了20多种新型单克隆抗体产品。他是几个新颖的产品和配方专利和申请的持有人。他一直通过早期发现研究直接参与几个成功的新型生物制剂，通过临床试验和商业化进入开发和制造。曾任职务包括2010年被百时美施贵宝（Bristol-Myers Squibb）收购的Mederex的执行董事、强生公司（Ethicon，OrthoBiotech&Pharmaceutical Research）和拜耳（Bayer）的首席发现科学职位。Cini博士在系统生物学的治疗领域包括肿瘤学，免疫肿瘤学，炎症，骨质疏松症，伤口愈合，手术粘连和细胞老化。Cini博士拥有北德克萨斯大学（University of North Texas）生物化学博士学位。
John K. Cini,co-founded Sonnet in 2015 and has since served as its Chief Scientific Officer, and was appointed Chief Scientific Officer of the Company at the closing of the Merger, where he oversees and directs the Company's discovery and development programs. His role includes the oversight of the selection process of cancer and immune oncology targets and proof-of-concept testing. Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics, Inc. from January 2011 to April 2015. Dr. Cini has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has also been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization. Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini's therapeutic areas of expertise in system biology include oncology, immune oncology, inflammation, osteoporosis, wound healing, surgical adhesion and cellular aging. Dr. Cini has a PhD in Biochemistry from University of North Texas.- John K.Cini，他于2015年共同创立十四行诗，并一直担任其首席科学官，并于合并结束时被任命为公司的首席科学官，在那里他负责监督和指导公司的发现和开发计划。他的角色包括监督癌症和免疫肿瘤学目标的选择过程和概念验证测试。在加入十四行诗之前，他曾于2011年1月至2015年4月担任OncoBiologics，Inc.的发现和开发科学Vice President。他从Discovery公司到IND公司成功推进了20多种新型单克隆抗体产品。他是几个新颖的产品和配方专利和申请的持有人。他一直通过早期发现研究直接参与几个成功的新型生物制剂，通过临床试验和商业化进入开发和制造。曾任职务包括2010年被百时美施贵宝（Bristol-Myers Squibb）收购的Mederex的执行董事、强生公司（Ethicon，OrthoBiotech&Pharmaceutical Research）和拜耳（Bayer）的首席发现科学职位。Cini博士在系统生物学的治疗领域包括肿瘤学，免疫肿瘤学，炎症，骨质疏松症，伤口愈合，手术粘连和细胞老化。Cini博士拥有北德克萨斯大学（University of North Texas）生物化学博士学位。
- John K. Cini,co-founded Sonnet in 2015 and has since served as its Chief Scientific Officer, and was appointed Chief Scientific Officer of the Company at the closing of the Merger, where he oversees and directs the Company's discovery and development programs. His role includes the oversight of the selection process of cancer and immune oncology targets and proof-of-concept testing. Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics, Inc. from January 2011 to April 2015. Dr. Cini has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has also been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization. Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini's therapeutic areas of expertise in system biology include oncology, immune oncology, inflammation, osteoporosis, wound healing, surgical adhesion and cellular aging. Dr. Cini has a PhD in Biochemistry from University of North Texas.
- Susan Dexter
Susan Dexter自2019年5月起担任十四行诗首席技术官，担任合同顾问，并在合并结束时被任命为公司全职首席技术官。她来到十四行诗，拥有三十多年的生物技术科学、制造和业务发展经验，曾直接参与三个初创公司，以及多个并购活动。她在CMC for Biologics Process Development的专业知识范围从细胞系开发、工艺开发到商业制造。从2008年9月到合并完成，德克斯特在莱瑟姆生物伤害集团（Latham BioPharm Group）担任董事总经理，负责提供产品开发服务，管理与动物毒理学前期、临床前毒理研究和CMC相关的活动和学科，包括IND备案，cGMP活动和其他相关cmc供应链活动的质量监督。她从XcelleRex，Inc.来到LBG，该公司是一家CDMO和生物处理一次性使用技术的开发商。从2004年4月到2008年9月，她曾担任Xcellerex公司的首席商务官。在加入Xcellerex之前，从1998年7月到2004年4月，她担任陶氏化学公司CDMO（2000年在Dexter女士的协助下收购的协作性生物联盟）的业务开发副总裁；担任Celltech Biologics的业务开发总监，该公司被生物CDMO Lonza Biologics收购。她从1986年到1998年7月在Celltech/Lonza。Dexter女士以优异的成绩持有华盛顿特区美国大学免疫学和市场营销双学位，以及哈佛大学律师谈判认证和非金融经理财务认证。1999年至2006年，她还担任伦敦大学学院生物工程系名誉教授，为研究生、博士和研究生专业人员讲授生物制剂管理设施项目的学分课程讲座和讲习班。
Susan Dexter,has served as a contract consultant to Sonnet in the capacity of Chief Technical Officer since May 2019 and was appointed full-time Chief Technical Officer of the Company at the closing of the Merger on April 1, 2020. Her role at Sonnet is to manage the operations for drug development from cell line development, through cGMP manufacturing of drug substance and clinical drug product, regulatory submissions to initiate human clinical trials, and supply chain for labeling/packaging and distribution to clinical depots. All activities fall under the FDA's Chemical Manufacturing and Controls for biological drugs ("CMC"). She is also responsible for drug supply and management of non-clinical animal studies in support of regulatory filings related to first-in-human studies. She came to Sonnet with more than thirty years of experience in biotechnology science, manufacturing and business development, having been directly involved in three start-up companies and multiple M&A activities. Her expertise in CMC for biologics process development ranges from cell line development to process development through commercial manufacturing. In her role as Managing Director at Latham Biopharm Group ("LBG") from September 2008 until the closing of the Merger, Ms. Dexter ran the Product Development service offering, managing the activities and disciplines related to pre- clinical toxicology studies, and CMC-related activities including IND filings, Quality oversight of cGMP activities and other related CMC supply chain activities. She came to LBG from Xcellerex, Inc., a CDMO and developer of single Sonnet Biotherapeutics Holdings, Inc. e technology for bioprocessing. She was Chief Business Officer at Xcellerex from April 2004 to September 2008. Prior to Xcellerex, from July 1998 to April 2004, she was VP of Business Development at The Dow Chemical Company's CDMO, an acquisition of Collaborative BioAlliance, facilitated by Ms. Dexter in 2000, and Assoc. Director of Business Development at Celltech Biologics, purchased by Lonza Biologics, a biologics CDMO. She worked at Celltech/Lonza from 1986 to July 1998. Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C., and certifications from Harvard University in 'Negotiations for Lawyers' and 'Finance for Non-financial Managers'. She was also Professor Emeritus at University College, London, Department of Bioengineering, teaching a credited course lecture and workshop in "Project managing of a biologics facility", to graduate, Ph.D. and post-graduate professionals, from 1999 to 2006. She has served as a non-executive board member for Sartorius Stedim Biotech since 2015, compensation committee member since 2019, and auditing committee member since 2022. In February 2023, Susan was appointed to the board of directors for a London, UK based company Virocell, a technology developer and CDMO for manufacture of viral vectors for cell and gene therapies.- Susan Dexter自2019年5月起担任十四行诗首席技术官，担任合同顾问，并在合并结束时被任命为公司全职首席技术官。她来到十四行诗，拥有三十多年的生物技术科学、制造和业务发展经验，曾直接参与三个初创公司，以及多个并购活动。她在CMC for Biologics Process Development的专业知识范围从细胞系开发、工艺开发到商业制造。从2008年9月到合并完成，德克斯特在莱瑟姆生物伤害集团（Latham BioPharm Group）担任董事总经理，负责提供产品开发服务，管理与动物毒理学前期、临床前毒理研究和CMC相关的活动和学科，包括IND备案，cGMP活动和其他相关cmc供应链活动的质量监督。她从XcelleRex，Inc.来到LBG，该公司是一家CDMO和生物处理一次性使用技术的开发商。从2004年4月到2008年9月，她曾担任Xcellerex公司的首席商务官。在加入Xcellerex之前，从1998年7月到2004年4月，她担任陶氏化学公司CDMO（2000年在Dexter女士的协助下收购的协作性生物联盟）的业务开发副总裁；担任Celltech Biologics的业务开发总监，该公司被生物CDMO Lonza Biologics收购。她从1986年到1998年7月在Celltech/Lonza。Dexter女士以优异的成绩持有华盛顿特区美国大学免疫学和市场营销双学位，以及哈佛大学律师谈判认证和非金融经理财务认证。1999年至2006年，她还担任伦敦大学学院生物工程系名誉教授，为研究生、博士和研究生专业人员讲授生物制剂管理设施项目的学分课程讲座和讲习班。
- Susan Dexter,has served as a contract consultant to Sonnet in the capacity of Chief Technical Officer since May 2019 and was appointed full-time Chief Technical Officer of the Company at the closing of the Merger on April 1, 2020. Her role at Sonnet is to manage the operations for drug development from cell line development, through cGMP manufacturing of drug substance and clinical drug product, regulatory submissions to initiate human clinical trials, and supply chain for labeling/packaging and distribution to clinical depots. All activities fall under the FDA's Chemical Manufacturing and Controls for biological drugs ("CMC"). She is also responsible for drug supply and management of non-clinical animal studies in support of regulatory filings related to first-in-human studies. She came to Sonnet with more than thirty years of experience in biotechnology science, manufacturing and business development, having been directly involved in three start-up companies and multiple M&A activities. Her expertise in CMC for biologics process development ranges from cell line development to process development through commercial manufacturing. In her role as Managing Director at Latham Biopharm Group ("LBG") from September 2008 until the closing of the Merger, Ms. Dexter ran the Product Development service offering, managing the activities and disciplines related to pre- clinical toxicology studies, and CMC-related activities including IND filings, Quality oversight of cGMP activities and other related CMC supply chain activities. She came to LBG from Xcellerex, Inc., a CDMO and developer of single Sonnet Biotherapeutics Holdings, Inc. e technology for bioprocessing. She was Chief Business Officer at Xcellerex from April 2004 to September 2008. Prior to Xcellerex, from July 1998 to April 2004, she was VP of Business Development at The Dow Chemical Company's CDMO, an acquisition of Collaborative BioAlliance, facilitated by Ms. Dexter in 2000, and Assoc. Director of Business Development at Celltech Biologics, purchased by Lonza Biologics, a biologics CDMO. She worked at Celltech/Lonza from 1986 to July 1998. Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C., and certifications from Harvard University in 'Negotiations for Lawyers' and 'Finance for Non-financial Managers'. She was also Professor Emeritus at University College, London, Department of Bioengineering, teaching a credited course lecture and workshop in "Project managing of a biologics facility", to graduate, Ph.D. and post-graduate professionals, from 1999 to 2006. She has served as a non-executive board member for Sartorius Stedim Biotech since 2015, compensation committee member since 2019, and auditing committee member since 2022. In February 2023, Susan was appointed to the board of directors for a London, UK based company Virocell, a technology developer and CDMO for manufacture of viral vectors for cell and gene therapies.
- Richard Kenny
Richard Kenny自2021年4月起担任我们的首席医疗官，担任合同顾问。Kenney博士在生物制剂的转化阶段开发以及临床前，临床阶段和商业化疫苗和免疫疗法的商业化策略和公司管理方面拥有超过20年的经验。作为Clinreg Biologics的总裁，他在生物制剂、医疗监测和药物警戒的临床和监管事务中提供了多个职位的战略咨询。他最近担任X-VAX Technology的首席发展官，此前曾担任Immune Design公司和Crucell Holland公司的首席医疗官，在那里他曾领导临床开发和监管事务小组。Kenney博士在FDA做了6年多的研究员/评审员，并在杜克大学和美国国立卫生研究院接受了研究生培训。Kenney博士在乔治华盛顿大学获得化学学士学位，在哈佛医学院获得医学博士学位。
Richard Kenny,has more than 20 years of experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics, he has provided strategic consulting in clinical and regulatory affairs of biologics and medical monitoring and pharmacovigilance in several capacities. As such, Dr. Kenney also serves as the CMO for Public Health Vaccines' Marburg vaccine program. He previously served as Chief Development Officer at X-VAX Technology and before that had Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.- Richard Kenny自2021年4月起担任我们的首席医疗官，担任合同顾问。Kenney博士在生物制剂的转化阶段开发以及临床前，临床阶段和商业化疫苗和免疫疗法的商业化策略和公司管理方面拥有超过20年的经验。作为Clinreg Biologics的总裁，他在生物制剂、医疗监测和药物警戒的临床和监管事务中提供了多个职位的战略咨询。他最近担任X-VAX Technology的首席发展官，此前曾担任Immune Design公司和Crucell Holland公司的首席医疗官，在那里他曾领导临床开发和监管事务小组。Kenney博士在FDA做了6年多的研究员/评审员，并在杜克大学和美国国立卫生研究院接受了研究生培训。Kenney博士在乔治华盛顿大学获得化学学士学位，在哈佛医学院获得医学博士学位。
- Richard Kenny,has more than 20 years of experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics, he has provided strategic consulting in clinical and regulatory affairs of biologics and medical monitoring and pharmacovigilance in several capacities. As such, Dr. Kenney also serves as the CMO for Public Health Vaccines' Marburg vaccine program. He previously served as Chief Development Officer at X-VAX Technology and before that had Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.
- Stephen McAndrew
Stephen McAndrew，自2020年2月起担任Sonnet BioTherapeutics，Inc.（“Prior Sonnet”）业务发展高级副总裁。在加入Prior Sonnet之前，McAndrew博士于2014年3月至2019年10月担任Oncobiologics，Inc.业务战略与发展高级副总裁，并于2012年2月至2014年3月担任业务发展副总裁。在加入Oncobiologics，Inc.之前，McAndrew博士曾于2001年至2011年在多家生物制药公司担任过各种业务开发职务。从1993年3月到2001年12月，McAndrew博士还在百时美施贵宝公司担任过越来越有责任感的多个职位，包括担任外部科学和技术部门内的生物技术许可总监。麦克安德鲁博士在俄亥俄大学获得分子和细胞生物学博士学位，在奥尔巴尼的纽约州立大学获得分子遗传学硕士学位，在奥斯威戈的纽约州立大学获得学士学位。
Stephen McAndrew,served as the Senior Vice President of Business Development of Sonnet BioTherapeutics, Inc. ("Prior Sonnet") from February 2020. Before joining Prior Sonnet, Dr. McAndrew served as the Senior Vice President of Business Strategy & Development at Oncobiologics, Inc. from March 2014 to October 2019 and as the Vice President of Business Development from February 2012 to March 2014. Prior to Oncobiologics, Inc., Dr. McAndrew served in various business development roles at several biopharmaceutical companies from 2001 to 2011. From March 1993 to December 2001, Dr. McAndrew also served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as the Director of Biotechnology Licensing within the External Science and Technology Department. Dr. McAndrew earned his Ph.D. in Molecular and Cellular Biology from Ohio University, an M.S in Molecular Genetics from the State University of New York at Albany and a B.S from the State University of New York at Oswego.- Stephen McAndrew，自2020年2月起担任Sonnet BioTherapeutics，Inc.（“Prior Sonnet”）业务发展高级副总裁。在加入Prior Sonnet之前，McAndrew博士于2014年3月至2019年10月担任Oncobiologics，Inc.业务战略与发展高级副总裁，并于2012年2月至2014年3月担任业务发展副总裁。在加入Oncobiologics，Inc.之前，McAndrew博士曾于2001年至2011年在多家生物制药公司担任过各种业务开发职务。从1993年3月到2001年12月，McAndrew博士还在百时美施贵宝公司担任过越来越有责任感的多个职位，包括担任外部科学和技术部门内的生物技术许可总监。麦克安德鲁博士在俄亥俄大学获得分子和细胞生物学博士学位，在奥尔巴尼的纽约州立大学获得分子遗传学硕士学位，在奥斯威戈的纽约州立大学获得学士学位。
- Stephen McAndrew,served as the Senior Vice President of Business Development of Sonnet BioTherapeutics, Inc. ("Prior Sonnet") from February 2020. Before joining Prior Sonnet, Dr. McAndrew served as the Senior Vice President of Business Strategy & Development at Oncobiologics, Inc. from March 2014 to October 2019 and as the Vice President of Business Development from February 2012 to March 2014. Prior to Oncobiologics, Inc., Dr. McAndrew served in various business development roles at several biopharmaceutical companies from 2001 to 2011. From March 1993 to December 2001, Dr. McAndrew also served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as the Director of Biotechnology Licensing within the External Science and Technology Department. Dr. McAndrew earned his Ph.D. in Molecular and Cellular Biology from Ohio University, an M.S in Molecular Genetics from the State University of New York at Albany and a B.S from the State University of New York at Oswego.